PI
OVID icon

PFG Investments’s Ovid Therapeutics OVID Stock Holding History

PFG Investments’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,975
Closed -$4.61K – 1148
2025
Q2 		$4.61K Buy
+13,975
New +$4.21K ﹤0.01% 1045

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PFG Investments's OVID Position: Q3 2025 in Review

PFG Investments sold out of Ovid Therapeutics (OVID) in Q3 2025, closing a stake of 13,975 shares — an estimated $4.61K sold.

PFG Investments first reported a position in OVID in Q2 2025 and held it in 1 quarter. The position peaked at $4.61K in Q2 2025. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

  • PFG Investments reported no remaining Ovid Therapeutics position as of Q3 2025 after selling out during the quarter.
  • PFG Investments sold 13,975 Ovid Therapeutics shares in Q3 2025, an estimated $4.61K.
  • PFG Investments first reported a position in Ovid Therapeutics in Q2 2025 and held it in 1 quarter.
  • PFG Investments's Ovid Therapeutics position peaked at $4.61K in Q2 2025.
  • 81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on PFG Investments's 13F filing for Q3 2025, filed 31 Oct 2025.